Mithra Signs License Agreement with Searchlight Pharma for Donesta in Canada
Shots:
- Mithra is eligible to receive ~$18.80M in licensing fees & regulatory and sales-related milestones along with royalties on total Canadian annual net sales
- Searchlight to get exclusive sales & marketing rights for Donesta in Canada in managing the symptoms of menopause & will be responsible for obtaining & maintaining regulatory approvals required to market and sell Donesta in Canada
- In 2022, Mithra highlighted an efficacy result from the P-III program of Donesta, the orally administered Estetrol (E4)-based hormone therapy product candidate in 2022, and safety results in 2023. The results further support marketing authorization filings in the US in H2’23 & Canada in 2024 while primary safety data are expected for the EU in H1’24
Ref: Globenewswire | Image: Mithra
Related News:- Mithra Signs a License Agreement with Alvogen for its Estelle in Hong Kong and Taiwan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
